Cargando…
The Real-Life Impact of mFOLFIRI-Based Chemotherapies on Elderly Patients—Should We Let It or Leave It?
SIMPLE SUMMARY: The oncologic treatment of elderly patients is going on with a lack of evidence due to their underrepresentation in clinical trials. Many data suggest that certain groups of elderly patients may benefit from the systemic treatment of their metastatic colorectal tumors. We performed r...
Autores principales: | Pécsi, Balázs, Mangel, László Csaba |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649926/ https://www.ncbi.nlm.nih.gov/pubmed/37958320 http://dx.doi.org/10.3390/cancers15215146 |
Ejemplares similares
-
Real-Life Effectivity of Dose Intensity Reduction of First-Line mFOLFIRI-Based Treatment of Metastatic Colorectal Cancers: Sometimes Less Is More
por: Pécsi, Balázs, et al.
Publicado: (2023) -
Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201
por: Takahashi, Shin, et al.
Publicado: (2023) -
Balanitis associated with FOLFIRI chemotherapy
por: Micevic, Goran, et al.
Publicado: (2017) -
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2018) -
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2019)